An Institution‐Specific Heparin Titration Nomogram: Development, Validation, and Assessment of Compliance
- 1 October 2001
- journal article
- clinical trial
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 21 (10) , 1167-1174
Abstract
Study Objective. To develop, validate, and assess compliance with a heparin titration nomogram.Design. Prospective, open‐label trial.Setting. University teaching hospital.Subjects. Patients admitted with heart failure who required therapy with intravenous unfractionated heparin.Intervention. An in vitro concentration‐response was determined by measuring activated partial thromboplastin times (aPTTs) on normal pooled plasma containing known concentrations of heparin. The therapeutic aPTT range was determined from the concentration‐response by using the therapeutic heparin concentration range of 0.2–0.4 U/ml (protamine neutralization). Patients were consecutively enrolled, and therapy was managed by using the heparin titration nomogram. Paired aPTT‐heparin concentrations were obtained, and nomogram validation was performed by comparing the in vitro and the ex vivo concentration‐responses with use of linear regression. Nomogram compliance also was assessed.Measurements and Main Results. The therapeutic aPTT ranges based on in vitro and ex vivo data were determined to be 45–72 seconds and 47–61 seconds, respectively. The ranges were significantly different (pConclusion. These results confirm that, even in a relatively homogeneous disease‐state patient population, in vitro data do not accurately predict ex vivo data. If in vitro data are used to develop an institution‐specific nomogram, a validation procedure should be used to ensure accuracy. Although 100% compliance to a nomogram may not be attainable, it should be expected. Therefore, a compliance rate of 88% is concerning and suggests a need for increased nursing and physician education.Keywords
This publication has 23 references indexed in Scilit:
- Use of a Heparin Nomogram for Treatment of Patients with Venous Thromboembolism in a Community HospitalThrombosis and Haemostasis, 1998
- Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage.Journal of Clinical Pathology, 1996
- The Weight-based Heparin Dosing Nomogram Compared with a Standard Care NomogramAnnals of Internal Medicine, 1993
- Establishing a Therapeutic Range for Heparin TherapyAnnals of Internal Medicine, 1993
- Heparin for 5 Days as Compared with 10 Days in the Initial Treatment of Proximal Venous ThrombosisNew England Journal of Medicine, 1990
- The Variations Between Heparin Sensitivity of Different Lots of Activated Partial Thromboplastin Time Reagent Produced by the Same ManufacturerAmerican Journal of Clinical Pathology, 1988
- Continuous Intravenous Heparin Compared with Intermittent Subcutaneous Heparin in the Initial Treatment of Proximal-Vein ThrombosisNew England Journal of Medicine, 1986
- Heparin Monitoring by Activated Partial Thromboplastin Time: Comparison of Ex Vivo Measurement and In Vitro Standardization.American Journal of Clinical Pathology, 1985
- Heparin kinetics: Variables related to disposition and dosageClinical Pharmacology & Therapeutics, 1981
- Heparin and the Activated Partial Thromboplastin Time — A Difference between theIn-vitroandIn-vivoEffects and Implications for the Therapeutic RangeAmerican Journal of Clinical Pathology, 1980